Phase 1/2 Study of LOXO-195 in Patients With Previously Treated NTRK Fusions or Non-fusion NTRK Cancers

Conditions:   Carcinoma, Non-Small-Cell Lung;   Thyroid Neoplasms;   Sarcoma;   Colorectal Neoplasms;   Salivary Gland Neoplasms;   Biliary Tract Neoplasms;   Brain Neoplasm, Primary;   Breast Ductal Carcinoma NOS;   Melanoma;   Solid Tumors Cancer of Unknown Primary;   Glioblastoma;   Bile Duct Neoplasms;   Astrocytoma;   Head and Neck Squamous Cell Carcinoma;   Pontine Glioma;   Pancreatic Neoplasms;   Ovarian Neoplasms;   Carcinoma, Renal Cell;   Cholangiocarcinoma;   Skin Carcinoma;   Carcinoma, Bronchogenic;   Bronchial Neoplasms;   Lung Neoplasms;   Respiratory Tract Neoplasms;   Thoracic Neoplasms;   Neoplasms, Nerve Tissue;   Nevi and Melanomas;   Intestinal Neoplasms;   Thyroid Cancer;   GIST;   Malignant Peripheral Nerve Sheath Tumors;   Breast Secretory Carcinoma;   Uterine Neoplasms
Intervention:   Drug: LOXO-195
Sponsor:   Loxo Oncology, Inc.
Recruiting - verified July 2017

http://ift.tt/2tHSfol